| Today’s Big NewsFeb 8, 2024 |
| By Nick Paul Taylor AstraZeneca has cut another strand of its multi-front IL-33 drug development program, stopping work in diabetic kidney disease in response to phase 2b efficacy data. |
|
|
|
By James Waldron BioNTech has already been tinkering with its manufacturing processes in the run up to CAR-T BNT211 entering pivotal trials. Now, the German biotech has brought British company Autolus on board in an intriguing $250 million collaboration. |
By James Waldron Apparently Kyverna Therapeutics wasn’t getting carried away when it raised its IPO expectations on Tuesday. |
Sponsored by ICON In this exclusive interview, ICON Biotech President Chris Smyth paints a picture of the operating environment facing biotechs in 2024. |
|
In addition to their standard consultative approach to CRO studies, BioIVT also provides gap analysis, interpretation and advice, submission or publication assistance, and other consulting... Read More >>
|
|
By Annalee Armstrong Almost a year ago to the day, Neurona Therapeutics was cutting staff, citing a difficult funding environment. Fast forward to today, and the company has reeled in a much needed $120 million. |
By Gabrielle Masson Adverum Biotechnologies’ gene therapy for wet age-related macular degeneration reduced treatment burden and maintained visual acuity in a phase 2 study, though a full picture can't be formed yet from the slice of early data. |
By Max Bayer Veru knows the route that its once-dismissed respiratory distress drug has to take to pacify regulators, but the biotech needs some more cash to hit the road. |
By Joseph Keenan Medidata, which provides analytics solutions for clinical trials, extended its partnership with Sanofi by signing a new pact with the French pharma's vaccine unit. |
By Fraiser Kansteiner While Catalent’s Bloomington, Indiana, site is no stranger to FDA reprimands, its latest write-up is notable given that the site forms part of the $16.5 billion deal Novo Holdings struck to acquire Catalent earlier this week. |
By Joseph Keenan H1, a healthtech company focused on AI, rolled out the latest addition to its Trial Landscape platform that was designed for use in clinical trial design and development. |
By Kevin Dunleavy With an upfront payment of $100 million, Kyowa Kirin has bought into a partnership with BridgeBio to develop and commercialize Truseltiq (infigratinib) in Japan. The treatment is in late-stage development to treat dwarfism. |
By Heather Landi Walgreens tapped Mary Langowski, who led growth strategies at CVS and Solera Health, to run its health services segment, the company announced Thursday. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
